THU0100 Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

B. Hsu; S. Sheng; J.S. Smolen; M.E. Weinblatt

doi:10.1136/annrheumdis-2012-eular.2065

THU0100 Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.2065 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 188.1-188 ◽

Cited By ~ 4

Author(s):

B. Hsu ◽

S. Sheng ◽

J.S. Smolen ◽

M.E. Weinblatt

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Phase 2 ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Dose Ranging

Download Full-text

OP0025 Results from a multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.1708 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 61.1-61 ◽

Cited By ~ 4

Author(s):

B. Hsu ◽

S. Sheng ◽

M.E. Weinblatt ◽

J.S. Smolen

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

FRI0181 Sirukumab, a human anti-IL-6 monoclonal antibody, improves physical function in patients with active ra despite methotrexate therapy: Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.2638 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 373.2-373 ◽

Cited By ~ 1

Author(s):

B. Hsu ◽

C.-F. Chiou ◽

S. Sheng ◽

J. Smolen ◽

M. Weinblatt

Keyword(s):

Monoclonal Antibody ◽

Physical Function ◽

Methotrexate Therapy ◽

Phase 2 ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Dose Ranging

Download Full-text

Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3523879 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double‐blind, Placebo‐controlled Phase 2 study

Arthritis & Rheumatology ◽

10.1002/art.41555 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study

Inflammation Research ◽

10.1007/s00011-019-01218-y ◽

2019 ◽

Vol 68 (4) ◽

pp. 261-274 ◽

Cited By ~ 1

Author(s):

David L. Boyle ◽

Samuel E. DePrimo ◽

Cesar Calderon ◽

Dion Chen ◽

Paul J. Dunford ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Mechanism Of Action ◽

Active Rheumatoid Arthritis ◽

Phase 2 ◽

Histamine H4 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

H4 Receptor ◽

Orally Active

Download Full-text

Faculty Opinions recommendation of Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.733519001.793576228 ◽

2020 ◽

Author(s):

Pedro Machado

Keyword(s):

Ankylosing Spondylitis ◽

Dose Finding ◽

Phase 2 ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-205137 ◽

2014 ◽

Vol 73 (9) ◽

pp. 1616-1625 ◽

Cited By ~ 110

Author(s):

Josef S Smolen ◽

Michael E Weinblatt ◽

Shihong Sheng ◽

Yanli Zhuang ◽

Benjamin Hsu

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Phase Ii ◽

Interleukin 6 ◽

Active Rheumatoid Arthritis ◽

Phase Ii Study ◽

Methotrexate Therapy ◽

Dose Finding ◽

Proof Of Concept

Download Full-text

Erratum: Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

Arthritis & Rheumatism ◽

10.1002/art.30103 ◽

2010 ◽

Vol 62 (11) ◽

pp. 3518-3518 ◽

Cited By ~ 1

Author(s):

Jonathan Kay ◽

Eric L. Matteson ◽

Bhaskar Dasgupta ◽

Peter Nash ◽

Patrick Durez ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging

Download Full-text

SAT0254 Safety and Tolerability of the Anti-C5ar Humanised Monoclonal Antibody NNC0151-0000 in Patients with Rheumatoid Arthritis: A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.3239 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 684.3-685 ◽

Cited By ~ 1

Author(s):

S. Daniluk ◽

B.K. Skrumsager ◽

P. Leszczynski

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Multiple Dose ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Trial

Download Full-text

FRI0169 Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with results observed by 2 weeks: Results of the phase 3, multicenter, double-blind, placebo-controlled trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.2626 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 368.3-369

Author(s):

M.E. Weinblatt ◽

C.O. Bingham ◽

A.M. Mendelsohn ◽

L. Kim ◽

M. Mack ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Controlled Trial ◽

Methotrexate Therapy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text